IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application Lab

Key Terms

fermentation medical

Fermentation is a manufacturing process in which living microbes or their enzymes convert sugars and other feedstocks into products like proteins, enzymes, alcohols, acids, or cultured food ingredients. Investors care because it determines how a product is made, its cost, scalability, quality consistency and regulatory oversight—think of microbes as tiny factory workers whose efficiency and safety influence profit margins and approval risks.

enzyme medical

An enzyme is a natural protein that speeds up specific chemical reactions in living things, acting like a specialized tool or a lock-and-key that makes a process happen faster and more efficiently. For investors, enzymes matter because they are often the targets or active components in drugs, diagnostics and industrial biotech processes; changes in enzyme science can affect a product’s effectiveness, manufacturing costs, regulatory outlook and therefore a company’s commercial and financial prospects.

enzymes medical

Enzymes are specialized proteins that speed up chemical reactions in living systems, acting like skilled workers on a biological assembly line to make processes happen faster and more efficiently. For investors, enzymes matter because they are often the active components behind drugs, diagnostic tests, and bio-manufacturing methods; their effectiveness, patent protection, production cost and regulatory approval can directly influence a biotech product’s commercial potential and a company’s financial prospects.

industrial biotechnology medical

Industrial biotechnology uses living cells or their components—such as microbes, enzymes, or plant cells—as tools to make chemicals, materials, fuels or ingredients in factories, akin to using baker’s yeast to turn flour into bread but on an industrial scale. Investors care because it can cut production costs, open access to novel or greener products, and shift supply chains, while also carrying technical development and regulatory risks that affect how profitable and fast commercialization can be.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BUENOS AIRES, Argentina & SÃO PAULO--(BUSINESS WIRE)-- IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — is enhancing regional production and innovation capabilities to better support the continued growth of its Health & Biosciences (H&B) business in Latin America, one of the fastest-growing markets for the company. The effort includes the transformation of the Arroyito site in Argentina into IFF’s first full fermentation‑based enzyme production hub in the region and the opening of a household care application laboratory at IFF’s Innovation Center in Brazil. Together, these enhancements expand IFF’s regional footprint and are expected to improve speed, reliability and locally relevant solutions for markets including brewing, animal nutrition, biofuels and home care.

IFF's home care application lab in Brazil.

“This is about turning science into impact where it matters most,” said Letícia Gonçalves, president of IFF H&B. “By bringing world‑class fermentation and application capabilities to Latin America, we are accelerating innovation for our customers and translating that into better food, more effective cleaning solutions and everyday products that improve quality of life for millions of consumers across the region.”

Building a regional enzyme production hub
IFF’s deep expertise in fermentation technology is at the heart of the Arroyito expansion, enabling the production of high‑performance enzymes through controlled biological processes that deliver consistent results under real‑world manufacturing conditions while reducing environmental impact. With the enhancements, IFF will now produce enzymes locally from the initial biological stage rather than relying solely on final processing and packaging steps, improving performance reliability, increasing processing efficiency and enabling faster adjustments as customer needs evolve across applications including brewing, animal nutrition, biofuels and home care.

Advancing applied innovation in home and personal Care
Complementing the Arroyito plant transformation, IFF’s new household care application laboratory in Brazil is designed to help customers evaluate and optimize enzyme performance under real regional conditions. The laboratory supports laundry and dishwashing applications, enabling faster testing, improved formulation accuracy and closer collaboration with customers developing next‑generation cleaning products.

“Latin America is a dynamic growth market for bioscience‑enabled solutions,” said Deia Vilela, vice president of Latin America for IFF H&B. “What’s most exciting is how this momentum is being shaped through deeper partnerships with customers and teams across the region, creating a strong foundation for sustained innovation and shared growth in the years ahead.”

Building on more than four decades of industrial biotechnology leadership, IFF’s investment reinforces its long‑term commitment to the region and positions its Health & Biosciences business to capture future growth across food, home and personal care, animal nutrition and bio‑industrial markets.

Cautionary Statement under the Private Securities Litigation Reform Act of 1995
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “”plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.

Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ^SM or ^® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310253993/en/

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

Source: IFF